At week 24, the treatment group had lower fasting blood glucose (p < 0.02) and improved insulin sensitivity (QUICKI, p = 0.02), and indicated a trend toward lower insulin resistance (HOMA-IR, p = 0.05) compared with the control. Here, INS is linked to Insulin resistance.